New diabetes clinical trial: A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Published on: August 19, 2025 at 11:00PM
Conditions: Hepatocellular Carcinoma; Immunotherapy; Preoperative; PD-1; CTLA-4
Interventions: Procedure: Radical surgery; Procedure: TACE treatment; Drug: Iparomlimab and Tuvonralimab Injection (QL1706); Drug: Lenvatinib
Sponsors: The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
https://ift.tt/XqS47jw
Conditions: Hepatocellular Carcinoma; Immunotherapy; Preoperative; PD-1; CTLA-4
Interventions: Procedure: Radical surgery; Procedure: TACE treatment; Drug: Iparomlimab and Tuvonralimab Injection (QL1706); Drug: Lenvatinib
Sponsors: The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting
https://ift.tt/XqS47jw
Comments
Post a Comment